Registered interventional antibody-drug conjugate trials
RecordSTO-ESX2PB9WV8-142XQJGBRK-G8RHSW
Global · as of 27 Sep 2026
Registered interventional antibody-drug conjugate trials worldwide were 2,351 (ClinicalTrials.gov, published 27 September 2026).
- Publisher
- ClinicalTrials.gov
- Authority tier
- T1 Official
- Locator
- totalCount field of the API response. Query: All interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others), any start date, as registered on 2026-09-27.
- Retrieved
- 27 Sep 2026
- Status
- Verified
What the source says
{"totalCount":2351,"studies":[
Checked: the figure 2,351 is stated in this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
APA
ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: All interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others), any start date, as registered on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_ESX2PB9WV8142XQJGBRKG8RHSW
Other formats: MLA, Chicago, BibTeX
- MLA
- ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: All interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others), any start date, as registered on 2026-09-27." 2026, https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId. Accessed 27 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_ESX2PB9WV8142XQJGBRKG8RHSW.
- Chicago
- ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: All interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others), any start date, as registered on 2026-09-27." 2026. https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId. Accessed September 27, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_ESX2PB9WV8142XQJGBRKG8RHSW.
- BibTeX
- @misc{clinicaltrialsgo2026ctgovg8rhsw, author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}}, title = {ClinicalTrials.gov study count: All interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others), any start date, as registered on 2026-09-27}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_ESX2PB9WV8142XQJGBRKG8RHSW}, note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\%22antibody-drug\%20conjugate\%22\%20OR\%20\%22antibody\%20drug\%20conjugate\%22\%20OR\%20deruxtecan\%20OR\%20vedotin\%20OR\%20govitecan\%20OR\%20emtansine\%20OR\%20ozogamicin\%20OR\%20tesirine\%20OR\%20mafodotin\%20OR\%20soravtansine\%20OR\%20tirumotecan\%20OR\%20rezetecan\%20OR\%20\%22SKB264\%22\%20OR\%20\%22SHR-A1811\%22\%20OR\%20\%22BL-B01D1\%22\%20OR\%20izalontamab\%20OR\%20disitamab\%20OR\%20\%22trastuzumab\%20deruxtecan\%22\%20OR\%20DS-8201\%20OR\%20T-DXd\%20OR\%20SHR-A1811\%20OR\%20\%22trastuzumab\%20rezetecan\%22\%20OR\%20\%22sacituzumab\%20tirumotecan\%22\%20OR\%20SKB264\%20OR\%20sac-TMT\%20OR\%20MK-2870\%20OR\%20\%22disitamab\%20vedotin\%22\%20OR\%20RC48\%20OR\%20\%22sacituzumab\%20govitecan\%22\%20OR\%20IMMU-132\%20OR\%20\%22enfortumab\%20vedotin\%22\%20OR\%20BL-B01D1\%20OR\%20\%22datopotamab\%20deruxtecan\%22\%20OR\%20Dato-DXd\%20OR\%20DS-1062\&filter.advanced=AREA\%5BStudyType\%5DINTERVENTIONAL\&countTotal=true\&pageSize=1\&fields=NCTId. Accessed September 27, 2026.} }
Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Primary source
- Publisher
- ClinicalTrials.gov (U.S. National Library of Medicine) · homepage ↗
- Authority tier
- Tier 1 · Multilateral Official
- Report
- ClinicalTrials.gov study count: All interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others), any start date, as registered on 2026-09-27
- Type
- Dataset
- Published
- —
- Locator
- totalCount field of the API response. Query: All interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others), any start date, as registered on 2026-09-27.
- Retrieved
- 27 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- Public domain
Verification
- Status
- Verified
- Review protocol
- pipeline:ctgov-api-totalcount-verified
- Checked on
- 27 September 2026
- Last revision
- 27 September 2026
- Permanent URL
- /stat/stat_ESX2PB9WV8142XQJGBRKG8RHSW